316 related articles for article (PubMed ID: 20674013)
41. Expression of VEGFR-1 (Flt-1) in breast cancer is associated with VEGF expression and with node-negative tumour stage.
Schmidt M; Voelker HU; Kapp M; Dietl J; Kammerer U
Anticancer Res; 2008; 28(3A):1719-24. PubMed ID: 18630531
[TBL] [Abstract][Full Text] [Related]
42. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer.
Seto T; Higashiyama M; Funai H; Imamura F; Uematsu K; Seki N; Eguchi K; Yamanaka T; Ichinose Y
Lung Cancer; 2006 Jul; 53(1):91-6. PubMed ID: 16697074
[TBL] [Abstract][Full Text] [Related]
43. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844
[TBL] [Abstract][Full Text] [Related]
44. Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells.
List AF; Glinsmann-Gibson B; Stadheim C; Meuillet EJ; Bellamy W; Powis G
Exp Hematol; 2004 Jun; 32(6):526-35. PubMed ID: 15183893
[TBL] [Abstract][Full Text] [Related]
45. Expression of vascular endothelial growth factor receptors during male germ cell differentiation in the mouse.
Nalbandian A; Dettin L; Dym M; Ravindranath N
Biol Reprod; 2003 Sep; 69(3):985-94. PubMed ID: 12773425
[TBL] [Abstract][Full Text] [Related]
46. Enhanced bronchial expression of vascular endothelial growth factor and receptors (Flk-1 and Flt-1) in patients with chronic obstructive pulmonary disease.
Kranenburg AR; de Boer WI; Alagappan VK; Sterk PJ; Sharma HS
Thorax; 2005 Feb; 60(2):106-13. PubMed ID: 15681497
[TBL] [Abstract][Full Text] [Related]
47. Gestational diabetes mellitus is associated with increased pro-migratory activation of vascular endothelial growth factor receptor 2 and reduced expression of vascular endothelial growth factor receptor 1.
Troncoso F; Acurio J; Herlitz K; Aguayo C; Bertoglia P; Guzman-Gutierrez E; Loyola M; Gonzalez M; Rezgaoui M; Desoye G; Escudero C
PLoS One; 2017; 12(8):e0182509. PubMed ID: 28817576
[TBL] [Abstract][Full Text] [Related]
48. Expression of vascular endothelial growth factor receptor types 1, 2 and 3 in placenta from pregnancies complicated by hypertensive disorders.
Marini M; Vichi D; Toscano A; Zappoli Thyrion GD; Parretti E; Mello G; Gheri G; Pacini A; Sgambati E
Reprod Fertil Dev; 2007; 19(5):641-51. PubMed ID: 17601412
[TBL] [Abstract][Full Text] [Related]
49. Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies.
Helske S; Vuorela P; Carpén O; Hornig C; Weich H; Halmesmäki E
Mol Hum Reprod; 2001 Feb; 7(2):205-10. PubMed ID: 11160848
[TBL] [Abstract][Full Text] [Related]
50. Hypoxia is responsible for soluble vascular endothelial growth factor receptor-1 (VEGFR-1) but not for soluble endoglin induction in villous trophoblast.
Munaut C; Lorquet S; Pequeux C; Blacher S; Berndt S; Frankenne F; Foidart JM
Hum Reprod; 2008 Jun; 23(6):1407-15. PubMed ID: 18413304
[TBL] [Abstract][Full Text] [Related]
51. Is fetal macrosomia in adequately controlled diabetic women the result of a placental defect?--a hypothesis.
Desoye G; Korgun ET; Ghaffari-Tabrizi N; Hahn T
J Matern Fetal Neonatal Med; 2002 Apr; 11(4):258-61. PubMed ID: 12375681
[TBL] [Abstract][Full Text] [Related]
52. Placental expression of vascular endothelial growth factor receptor-1/soluble vascular endothelial growth factor receptor-1 correlates with severity of clinical preeclampsia and villous hypermaturity.
Taché V; LaCoursiere DY; Saleemuddin A; Parast MM
Hum Pathol; 2011 Sep; 42(9):1283-8. PubMed ID: 21334711
[TBL] [Abstract][Full Text] [Related]
53. The relationship between transplacental O2 diffusion and placental expression of PlGF, VEGF and their receptors in a placental insufficiency model of fetal growth restriction.
Regnault TR; de Vrijer B; Galan HL; Davidsen ML; Trembler KA; Battaglia FC; Wilkening RB; Anthony RV
J Physiol; 2003 Jul; 550(Pt 2):641-56. PubMed ID: 12740423
[TBL] [Abstract][Full Text] [Related]
54. Expression of VEGF receptors VEFGR-1 and VEGFR-2, angiopoietin receptors Tie-1 and Tie-2 in chorionic villi tree during early pregnancy.
Demir R
Folia Histochem Cytobiol; 2009 Jan; 47(3):435-45. PubMed ID: 20164029
[TBL] [Abstract][Full Text] [Related]
55. [Ultrastructural examination of the placenta in pregnancy complicated by diabetes mellitus].
Pietryga M; Biczysko W; Wender-Ozegowska E; Brazert J; Biegańska E; Biczysko R
Ginekol Pol; 2004 Feb; 75(2):111-8. PubMed ID: 15108582
[TBL] [Abstract][Full Text] [Related]
56. Angiogenesis in gestational vascular complications.
Yagel S
Thromb Res; 2011 Feb; 127 Suppl 3():S64-6. PubMed ID: 21262445
[TBL] [Abstract][Full Text] [Related]
57. Differential expression of vascular endothelial growth factor (VEGF), endocrine gland derived-VEGF, and VEGF receptors in human placentas from normal and preeclamptic pregnancies.
Chung JY; Song Y; Wang Y; Magness RR; Zheng J
J Clin Endocrinol Metab; 2004 May; 89(5):2484-90. PubMed ID: 15126581
[TBL] [Abstract][Full Text] [Related]
58. Fetal insulin and IGF-II contribute to gestational diabetes mellitus (GDM)-associated up-regulation of membrane-type matrix metalloproteinase 1 (MT1-MMP) in the human feto-placental endothelium.
Hiden U; Lassance L; Tabrizi NG; Miedl H; Tam-Amersdorfer C; Cetin I; Lang U; Desoye G
J Clin Endocrinol Metab; 2012 Oct; 97(10):3613-21. PubMed ID: 22893718
[TBL] [Abstract][Full Text] [Related]
59. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences.
Tsatsaris V; Goffin F; Munaut C; Brichant JF; Pignon MR; Noel A; Schaaps JP; Cabrol D; Frankenne F; Foidart JM
J Clin Endocrinol Metab; 2003 Nov; 88(11):5555-63. PubMed ID: 14602804
[TBL] [Abstract][Full Text] [Related]
60. High early uterine vascular resistance values increase the risk of adverse pregnancy outcome independently from placental VEGF and VEGFR1 reactivities.
Valent S; Németh J; Sára L; Gidai J; Tóth P; Schaff Z; Paulin F; Pajor A
Eur J Obstet Gynecol Reprod Biol; 2011 Jun; 156(2):165-70. PubMed ID: 21349629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
